Compare ATEC & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEC | IRON |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.4B |
| IPO Year | 2006 | N/A |
| Metric | ATEC | IRON |
|---|---|---|
| Price | $19.88 | $90.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $22.00 | ★ $108.83 |
| AVG Volume (30 Days) | ★ 2.1M | 560.9K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $728,020,000.00 | N/A |
| Revenue This Year | $26.83 | N/A |
| Revenue Next Year | $16.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.11 | N/A |
| 52 Week Low | $8.70 | $30.82 |
| 52 Week High | $22.66 | $99.50 |
| Indicator | ATEC | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 53.38 |
| Support Level | $19.77 | $90.40 |
| Resistance Level | $21.42 | $94.51 |
| Average True Range (ATR) | 0.68 | 3.70 |
| MACD | -0.36 | -0.60 |
| Stochastic Oscillator | 5.54 | 32.55 |
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.